NCT00005579View on ClinicalTrials.gov

Dolastatin 10 in Treating Patients With Indolent Lymphoma, Waldenstrom's Macroglobulinemia, or Chronic Lymphocytic Leukemia

PHASE2CompletedINTERVENTIONAL
Timeline

Start Date

June 30, 1998

Study Completion Date

February 28, 2003

Conditions
LeukemiaLymphoma
Interventions
DRUG

dolastatin 10

Trial Locations (4)

21201

Marlene and Stewart Greenebaum Cancer Center, University of Maryland, Baltimore

48201-1379

Barbara Ann Karmanos Cancer Institute, Detroit

43210-1240

Arthur G. James Cancer Hospital - Ohio State University, Columbus

05401-3498

Vermont Cancer Center, Burlington

All Listed Sponsors
collaborator

National Cancer Institute (NCI)

NIH

lead

University of Vermont

OTHER

NCT00005579 - Dolastatin 10 in Treating Patients With Indolent Lymphoma, Waldenstrom's Macroglobulinemia, or Chronic Lymphocytic Leukemia | Biotech Hunter | Biotech Hunter